Retraction highlights data integrity concerns regarding lncRNA FBXL19-AS1 impacts on osteosarcoma cells, suggesting critical scrutiny is essential.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: